NL-OMON33553已完成不适用
Sentinel Node and Recurrent Breast Cancer; Regional staging proposal and registration - SNARB
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-Operable cytological /histological confirmed locally recurrent breast cancer
- •-Having obtained an informed consent
排除标准
- •-Proven ipsi- or contralateral regional lymph node metastases (ultrasound and FNA)
- •-Known to be allergic to *99mTc-colloidal albumin* or blue dye injection fluids
研究者
相似试验
进行中（未招募）
1 期
A Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple SclerosisRelapsing Multiple SclerosisMedDRA version: 17.1Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-024477-39-GBBiogen Idec Limited1,600
进行中（未招募）
1 期
A Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple SclerosisRelapsing Multiple SclerosisMedDRA version: 14.1Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-024477-39-GRBiogen Idec Limited1,600
进行中（未招募）
不适用
A Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple SclerosisRelapsing Multiple SclerosisMedDRA version: 17.1Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-024477-39-BEBiogen Idec Limited1,600
已完成
3 期
To determine if BIIB017 is safe and tolerable enough in patients with Relapsing Multiple Sclerosis on a long term duration.CTRI/2011/12/002229Biogen Idec1,500
进行中（未招募）
不适用
A Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple SclerosisEUCTR2010-024477-39-ESBiogen Idec Limited1,600